Stockwatch: Hopping on and off the inversion train
This article was originally published in Scrip
Executive Summary
As we move another week closer to the US Congressional mid–term elections, the prospect of any real legislative interruption to the life science inversion train continues to diminish. Inversions are where pharmaceutical and specialty pharmaceutical companies buy smaller foreign rivals to gain, amongst other advantages, their target's lower tax rate on the combined company's total profits.